GLP-1
-
healthFDA Approves Eli Lilly’s Oral GLP-1 Weight-Loss Pill Foundayo
The FDA has fast-tracked approval of Foundayo, Eli Lilly’s once-daily oral GLP-1 pill for obesity and overweight adults with comorbidities, following rapid clinical results and safety warnings.
-
healthExperts Divided on Microdosing Ozempic for Longevity
Top medical professionals clash over the safety and efficacy of microdosing GLP-1 drugs like Ozempic for metabolic health and longevity beyond approved indications.
-
healthHormone Therapy Boosts Weight Loss Drug Results by 35% in Postmenopausal Women
Mayo Clinic study shows menopausal hormone therapy combined with tirzepatide increases weight loss by 35% in women versus drug alone.
-
healthDiscontinuing GLP-1 Treatment Raises Cardiovascular Risk in Diabetic Patients
Study shows stopping GLP-1 drugs increases risk of heart disease in Type 2 diabetes patients.
-
healthPython Blood Holds Key to Healthy Weight Loss
A groundbreaking study identifies a molecule in python blood that could revolutionize weight loss and muscle health. Scientists find pTOS, which signals satiety and reduces appetite without side effects.
-
healthPython Blood Metabolite Shows Promise for Weight Loss
A metabolite in python blood suppresses appetite in mice without typical side effects of GLP-1 drugs like Ozempic.
-
healthGLP-1 Drugs Show Heart Attack Recovery Potential
New research reveals Ozempic-like drugs may reduce heart damage after a heart attack by restoring blood flow through capillaries, offering a promising new therapeutic pathway.
-
healthWeight-Loss Drug Semaglutide Linked to Lower Mental Health Risks
New study shows semaglutide significantly reduces risks of depression, anxiety, and self-harm in patients with obesity or diabetes.